Drug Trial Radar · NCT03526835
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
560
Planned (sponsor's estimate)
Start
May 2, 2018
Primary completion
May 2028
Study completion Nov 2028
Sponsor
- Lead sponsor
- GenmabIndustry
- Sponsor type
- Industry
- First posted
- May 16, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC. The dose escalation part has been completed and the RP2D will be further evaluated in an expansion part of the study. Cohorts of selected solid tumor indications for which there is evidence of EGFR dependency and potential sensitivity to EGFR inhibition will be evaluated including head and neck cancer and metastatic colorectal cancer (mCRC). The study will further assess the safety, tolerability, PK, PD, immunogenicity, and anti-tumor activity of MCLA-158 in monotherapy or in combination with other therapies.
Conditions
- Advanced/Metastatic Solid Tumors
- Colorectal Cancer
- Gastric Cancer
- Gastroesophageal-junction Cancer
- NSCLC
- HNSCC
- Head and Neck Squamous Cell Carcinoma
- Esophageal Cancer
Interventions
MCLA-158Drug
full-length IgG1 bispecific antibody targeting EGFR and LGR5
MCLA-158 + PembrolizumabCombination product
MCLA-158 in combination with pembrolizumab will be explored first in HNSCC patients eligible to receive pembrolizumab as first-line monotherapy.
MCLA-158 + FOLFIRICombination product
MCLA-158 in combination with FOLFIRI will be explored in mCRC patients with up to 1 line of prior regimen.
MCLA-158 + FOLFOXCombination product
MCLA-158 in combination with FOLFOX will be explored in mCRC patients with up to 1 line of prior regimen.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Escalation: Number of patients with Dose Limiting Toxicities (DLTs) during Cycle 1Time frame: 4 weeks
- Expansion (Single agent - randomized expansion in 2/3L Head and Neck cancer, and combination cohorts): Safety and tolerability: AEs and SAEsTime frame: 6-12 months
- Expansion (Single agent - randomized expansion in 2/3L Head and Neck cancer): Treatment discontinuations and dose modifications due to AEsTime frame: 6-12 months
- Expansion (single agent - randomized expansion in 2/3L Head and Neck cancer): Best overall response (BOR)Time frame: 36 months
- Expansion (Single agent - non-randomized, and combination cohorts): Objective response rate (ORR)Time frame: 36 months
- Expansion (single agent - randomized expansion in 2/3L Head and Neck cancer): exposure-safety relationship of petosemtamab administered at 1100 mg and 1500 mg: TEAEsTime frame: 8 weeks
- Expansion: (subcutaneous cohort): Bioavailability of subcutaneous vs intravenous administrationTime frame: 6 weeks
- Expansion: (subcutaneous cohort): Area under the concentration versus time curve from time zero to time t [AUC0-t]Time frame: 6 weeks
- Expansion: (subcutaneous cohort): Maximum plasma concentration [Cmax]Time frame: 8 weeks
- Expansion: (subcutaneous cohort): Minimum plasma drug concentration [Ctrough]Time frame: 6 weeks
Locations
54 sites in 7 countries. Site status is shown where the registry gives one.
UCSD
La Jolla, California · Recruiting
USC Norris Comprehensive Cancer Center
Los Angeles, California · Active not recruiting
Sharp Healthcare
San Diego, California · Recruiting
Rocky Mountain Cancer Centers
Lone Tree, Colorado · Recruiting
Florida Cancer Specialists
Fort Myers, Florida · Completed
University of Florida
Gainesville, Florida · Recruiting
Sarah Cannon Research Institute (Lake Nona)
Orlando, Florida · Recruiting
Emory University
Atlanta, Georgia · Recruiting
Massachusetts General Hospital - Dana Farber
Boston, Massachusetts · Recruiting
Karmanos Cancer Institute
Detroit, Michigan · Completed
SSM Health Saint Louis University Hospital
St Louis, Missouri · Completed
Washington University School of Medicine at St Louis
St Louis, Missouri · Recruiting
Cayuga Medical Center
Ithaca, New York · Recruiting
Mt. Sinai
New York, New York · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
Hematology-Oncology Associates of Central New York
Syracuse, New York · Recruiting
Cleveland Clinic
Cleveland, Ohio · Recruiting
Ohio State University
Columbus, Ohio · Recruiting
Taylor Cancer Research Center
Maumee, Ohio · Recruiting
SSM OKC Hightower Clinical
Oklahoma City, Oklahoma · Completed
University of Pennsylvania
Philadelphia, Pennsylvania · Recruiting
The University Of Tennessee Health Science Center
Memphis, Tennessee · Recruiting
Sarah Cannon Research Institute
Nashville, Tennessee · Completed
Texas Oncology
Dallas, Texas · Recruiting
Oncology Consultants
Houston, Texas · Recruiting
Texas Oncology
Tyler, Texas · Recruiting
Utah Cancer Specialists
Salt Lake City, Utah · Recruiting
University of Utah Health Huntsman Cancer Hospital
Salt Lake City, Utah · Recruiting
Oncology & Hematology Associates of Southwest Virginia
Roanoke, Virginia · Recruiting
Georgetown University Medical Center
Georgetown, Washington · Recruiting
Cancer Care Northwest
Spokane, Washington · Recruiting
Cliniques universitaires Saint-Luc
Brussels, Belgium · Recruiting
Institut Jules Bordet
Brussels, Belgium · Completed
UZ Gent
Ghent, Belgium · Recruiting
Chu Ucl Namur Site De Sainte-Elisabeth
Namur, Belgium · Recruiting
Hopital Saint Andre, CHU Bordeaux
Bordeaux, France · Recruiting
Centre Leon Berard
Lyon, France · Recruiting
Hopital La Timone
Marseille, France · Active not recruiting
Institut Régional du Cancer de Montpellier
Montpellier, France · Recruiting
Centre Antoine Lacassagne
Nice, France · Recruiting
Showing 40 of 54 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.